XAIR
Beyond Air Inc.
Company Overview
| Mkt Cap | $11.65M | Price | $1.31 |
| Volume | 103.64K | Change | +6.50% |
| P/E Ratio | -0.2 | Open | $1.23 |
| Revenue | $3.7M | Prev Close | $1.23 |
| Net Income | $-46.6M | 52W Range | $1.19 - $13.52 |
| Div Yield | N/A | Target | $11.50 |
| Overall | 34 | Value | 60 |
| Quality | -- | Technical | 9 |
No chart data available
About Beyond Air Inc.
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through two segments, Beyond Air and Beyond Cancer. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. In addition, the company develops ultra-high concentration NO in Phase 1 clinical trial to treat solid tumors. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Latest News
Analysts Are Bullish on These Healthcare Stocks: Beyond Air (XAIR), Diamedica Therapeutics (DMAC)
BTIG Sticks to Its Hold Rating for Beyond Air (XAIR)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | XAIR | $1.31 | +6.5% | 103.64K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |